Bioalmanac
Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408
A small peptide reported as vastly more potent than BDNF at forming new synapses in animals. No human has been studied on it, and the potency is the concern, not the selling point.
Storage
- Freeze-dried powder
- Powder refrigerated at 2–8 °C, protected from light and moisture.
- After mixing
- In a carrier solution, refrigerated and used within weeks. Stability in DMSO or similar carriers has not been characterised.
- Long-term, frozen
- Powder is stable at −20 °C or colder.
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Commonly described community protocol | 5000–20000 mcg | Once daily, often in short courses | Community practice |
When to stop
- Any new neurological symptom: persistent headache, visual change, unusual mood change, confusion or seizure activity. Seek medical assessment.
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
- Any new lump, unexplained weight loss or unexplained persistent pain.
- Skin irritation where a transdermal carrier is applied.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.